![](https://aiolux-shared.s3.us-east-2.amazonaws.com/aiolux-logo-mid.png)
Check out Investor Copilot custom GPT, which lets you enjoy ChatGPT functionality with recent financial information
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
[ADAP] Adaptimmune Therapeutics plc - Total Non-Current Liabilities
Data updated 2024-Mar-23 (Saturday)Note: Detailed Statistics for Total Non-Current Liabilities in Balance Sheet for Adaptimmune Therapeutics plc [NASDAQ:ADAP] with frequency distribution chart that analyze trends & history . Total Non-Current Liabilities are obligations of Company due after one year. View Balance Sheet for broader context
Share
Quarterly Total Non-Current Liabilities values for Adaptimmune Therapeutics plc are rounded to enhance readability
2023-Dec | 2023-Sep | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sep | |
---|---|---|---|---|---|---|
Total Non-Current Liabilities | 170 M | 133 M | 140 M | 141 M | 183 M | 153 M |
Sequential Quarter Growth | +27.7% | -4.9% | -0.3% | -23.0% | +19.5% | -11.5% |
Quarter-on Quarter Growth | -6.7% | -12.7% | -18.8% | -26.2% | -9.2% | +114.0% |
Annual Total Non-Current Liabilities values for Adaptimmune Therapeutics plc are rounded to enhance readability
2023-Dec | 2022-Dec | 2021-Dec | 2020-Dec | 2019-Dec | 2018-Dec | |
---|---|---|---|---|---|---|
Total Non-Current Liabilities | 170 M | 183 M | 201 M | 70.8 M | 23.6 M | 5.41 M |
Year-on-Year Growth | -6.7% | -9.2% | +183.8% | +200.6% | +335.2% | +40.7% |
2-yr CAGR | -8.0% | +60.5% | +192.1% | +261.7% | +147.4% | -56.1% |
3-yr CAGR | +34.0% | +97.9% | +233.6% | +164.0% | -5.7% | |
4-yr CAGR | +64.0% | +141.0% | +168.8% | +26.0% | ||
5-yr CAGR | +99.3% | +116.4% | +48.2% |
Frequency distribution of quarterly Total Non-Current Liabilities values from 2015-Sep-30 grouped into buckets. Latest Total Non-Current Liabilities value is 170 Million as of 2023-Dec-31
Subsequent stock performance post earnings date till next announcement for Adaptimmune Therapeutics plc mapped with quarterly Total Non-Current Liabilities values reported at that time. Most recent value denoted with star
Select frequency and calculation type for Total Non-Current Liabilities above for vertical axis in scatter chart. Additionally choose type of performance for horizontal axis
Bayesian (Conditional Probability) analysis for Adaptimmune Therapeutics plc with subsequent post-earnings performance given Total Non-Current Liabilities values. Analysis uses quarterly data and subsequent absolute performance. Most recent quarter is denoted with a star and corresponding partial performance is excluded from calculations
Underperform (absolute perf.) | Outperform (absolute perf.) | |
---|---|---|
Total Non-Current Liabilities - Low | 47% | 53% |
Total Non-Current Liabilities - Medium | 38% | 62% |
Total Non-Current Liabilities - High | 71% | 29% |
Total Non-Current Liabilities (Sequential growth %) - Low | 38% | 62% |
Total Non-Current Liabilities (Sequential growth %) - Medium | 71% | 29% |
Total Non-Current Liabilities (Sequential growth %) - High | 41% | 59% |
Total Non-Current Liabilities (QoQ growth %) - Low | 71% | 29% |
Total Non-Current Liabilities (QoQ growth %) - Medium | 23% | 77% |
Total Non-Current Liabilities (QoQ growth %) - High | 57% | 43% |
Related to Adaptimmune Therapeutics plc
Information for Adaptimmune Therapeutics plc
Current Detail : Recent daily/monthly performance & benchmark comparison
Historical Detail : Historical performance & related information using Time Machine
Financial Statements : Analyze Income Statement, Balance Sheet & Cashflow Statement and also compare with peers Currently Viewing
Bayesian Statement Classifier : Investigate historical financial statements to make probabalistic predictions using Artificial Intelligence
Anomaly Detection : Investigate unusual recent performance & technicals with historical context using AI
Historical Seasonality : Seasonal performance by calendar months
Technical History : Popular Technical indicator trends (RSI, MACD etc.)
Metric Deciles : Contextualizing recent performance & technical levels into historical decile buckets
Dollar Cost Averaging : Dollar Cost Average (DCA) over time in your portfolio
Moving Averages : Key Simple & Exponential Moving Averages
Historical Analogues : Insights from closest historical matches to recent performance using Artificial Intelligence
Chart Pattern Matching : Insights from similar historical charts to recent chart using Artificial Intelligence
News Stories : News stories on 2024-Jun-14 on Google
SEC Reports : Quarterly reports around 2024-Jun-14 on SEC Edgar
Compare Adaptimmune Therapeutics plc with other assets
Market Performance : Recent performance across covered assets
Historical Performance : Prior & Subsequent performance across assets on a historical date
Market Technicals : Technical indicator levels across covered assets
Market Seasonality : Seasonal performance by calendar months across covered assets
Pair Correlations : Performance Correlations with other assets
Beta : Volatility relative to the broad market
Performance Comparison : Visually compare/benchmark performance with other assets over time
Side-by-Side Comparison : Contrast with other assets over time in a side-by-side presentation
Sector : Health Care sector performance which includes Adaptimmune Therapeutics plc
Industry : Biotechnology industry performance which includes Adaptimmune Therapeutics plc